Table 1 Characteristics of patients with neuroimmunological disorders and analysis of peripheral blood mononuclear cells.
From: Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
Neuroimmunological patients | α-CD20 | control | p-values | |
|---|---|---|---|---|
number of subjects | 22 | 23 | ||
gender | female | 18 | 18 | |
male | 4 | 5 | ||
age [years] | mean (min. - max.) | 45 (18-69) | 42 (17-69) | |
α-CD20 treatment duration [months] | mean (min. - max.) | 15 (2-47) | n.a. | |
disorder | MS/CIS | 8 | 22 | |
NMO | 11 | 1 | ||
Myasthenia gravis | 2 | 0 | ||
autoimmune neuropathy | 1 | 0 | ||
CD19 + of all PBMCs | [mean % +/- SEM] | 0.2 (+/-0.1) | 7.9 (+/-1.1) | <0.0001 |
CD4 + of all PBMCs | " | 37.7 (+/-2.5) | 35.9 (+/-1.5) | 0.420 |
CD8 + of all PBMCs | " | 16.8 (+/-1.8) | 15.5 (+/-1.1) | 0.768 |
CD14 + of all PBMCs | " | 22.3 (+/-2.5) | 16.4 (+/-1.4) | 0.159 |
CD4 + of all CD4 + /CD8 + | " | 69.2 (+/-2.2) | 69.8 (+/-1.9) | 0.803 |
CD4 + of all CD4 + /CD8 + /CD14 + | " | 48.6 (+/-2.9) | 53.2 (+/-2.0) | 0.271 |
CD8 + of all CD4 + /CD8 + /CD14 + | " | 21.3 (+/-2.0) | 22.9 (+/-1.5) | 0.370 |
CD14 + of all CD4 + /CD8 + /CD14 + | " | 30.0 (+/-3.7) | 23.9 (+/-2.1) | 0.163 |
CD25 + CD127 - of all CD4 + | [median % with 20/80% percentile] | 6.8 (5.5-8.4) | 5.2 (4.3-6.8) | 0.022 |